Porton Pharma Solutions Ltd. provides contract development and manufacturing organization (CDMO) solutions for small molecules, tides, biologics, and conjugates from pre-clinical to commercial. It has a strategic collaboration with Aojin Life Sciences to advance XDC conjugate drugs; and strategic partnership with Dragon Sail Pharmaceutical to build a new ecosystem for ADC drug development, production, and supply chain. It also offers crystallization, bio catalysis, metal catalysis, flow chemistry, prep-chromatography, and milling. The company operates in China and internationally. Porton Pharma Solutions Ltd. was formerly known as Porton Fine Chemicals Ltd. and changed its name to Porton Pharma Solutions Ltd. in January 2018. The company was incorporated in 2005 and is headquartered in Chongqing, China.

Sector

Healthcare

Industry

Biotechnology

CEO

Ju, Nianfeng

Employees

4,214

Website

www.portonpharma.com

IPO Date

2014-01-29

Headquarters

No.7, Yuntu Road, Beibei District, Chongqing 400714, China

Socials

NEWSLETTER

View Data Providers

NEWSLETTER

View Data Providers

Gainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.

Porton Pharma Solutions 300363

Porton Pharma Solutions Earnings Call Summary

Porton Pharma Solutions Earnings

Transcripts

Events

About Porton Pharma Solutions Ltd.

Porton Pharma Solutions
300363